Gradientech in exclusive partnership with Hardy Diagnostics for the US and Canadian markets
The diagnostics company Gradientech today announces the exclusive partnership with Hardy Diagnostics for the commercialisation of its QuickMIC® system in the United States and Canada. QuickMIC is an ultra-rapid antibiotic susceptibility testing (AST) system designed to provide critical results for sepsis patients. Alongside this partnership, Hardy Diagnostics has decided to invest in Gradientech, becoming one of the company’s largest shareholders.“With QuickMIC already being implemented in several European hospitals and the 510(k) study of QuickMIC recently started at clinical sites in the